Deals and M&A - Articles - Page 138

Medilink, Biontech ink potential $1B for HER3-targeting ADC

Oct. 17, 2023

In its first significant partnering deal since being founded in 2020, Medilink Therapeutics Co. Ltd. licensed exclusive global rights to an antibody-drug conjugate (ADC) targeting HER3 to Biontech SE in exchange for an up-front payment of $70 million, with the possibility for additional payments tied to development, regulatory and commercial milestones exceeding $1 billion. Medilink retains rights in mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region.

Handshake with dollar sign and checkmark

Biopharma deals September 2023

Biopharma deals total $18.46B in September, including six $1B+ deals

Oct. 17, 2023

By Amanda Lanier

Through Q3 2023 biopharma values are down 4.5% year over year, with 1,007 deals valued at $130.58 billion this year, compared to 1,179 deals worth $136.73 billion in the same time period in 2022. Biopharma deals have averaged $14.51 billion per month this year, a decrease from 2022’s average of $17.18 billion per month. September deals outpaced the average of both years, reaching $18.46 billion.

Biomap, Sanofi strike potential $1B+ deal to co-map AI drug discovery modules

Oct. 17, 2023

By Marian (YoonJee) Chu

Sanofi SA will pay $10 million up front and potentially $1 billion down the road to build artificial intelligence (AI) drug discovery modules with Biomap – the Silicon Valley-based biotech led by Chinese billionaire, software engineer and serial entrepreneur Robin Li known for founding China’s largest internet search engine and AI platform, Baidu, in 2000.

Med-tech deals September 2023

Despite September slowdown, med-tech deal value hits $9.83B through Q3

Oct. 16, 2023

By Amanda Lanier

Med-tech deals are up 49.01% year over year, with the industry raising $9.83 billion through September in 2023, up from $6.59 billion in the same time frame last year. The number of deals, meanwhile, has decreased from 1,510 through Q3 2022 to 1,278 this year.

Biopharma deals September 2023

Biopharma deals total $18.46B in September, including six $1B+ deals

Oct. 13, 2023

By Amanda Lanier

Through Q3 2023 biopharma values are down 4.5% year over year, with 1,007 deals valued at $130.58 billion this year, compared to 1,179 deals worth $136.73 billion in the same time period in 2022. Biopharma deals have averaged $14.51 billion per month this year, a decrease from 2022’s average of $17.18 billion per month. September deals outpaced the average of both years, reaching $18.46 billion.

Medilink, Biontech ink potential $1B for HER3-targeting ADC

Oct. 12, 2023

In its first significant partnering deal since being founded in 2020, Medilink Therapeutics Co. Ltd. licensed exclusive global rights to an antibody-drug conjugate (ADC) targeting HER3 to Biontech SE in exchange for an up-front payment of $70 million, with the possibility for additional payments tied to development, regulatory and commercial milestones exceeding $1 billion. Medilink retains rights in mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region.

OX40 latecomer Astria paying up to $320M for Ichnos portfolio; best-in-class prospect?

Oct. 12, 2023

By Randy Osborne

Astria Therapeutics Inc.’s potential $320 million deal with Ichnos Sciences Inc. to bring aboard an OX40 portfolio for atopic dermatitis puts the firm in line to compete with big pharma, which is trying – at a much later stage – the same mechanism of action.

EU orders Illumina to sell Grail or face further fines

Oct. 12, 2023

By Shani Alexander

The European Commission (EC) has ordered Illumina Inc. to sell Grail Inc. after it closed the acquisition without approval from EU regulators. The EC said that if Illumina fails to comply with the order, the company faces fines of up to 5% of its daily aggregate revenue or up to 10% of its annual worldwide revenue.

Biomap, Sanofi strike potential $1B+ deal to co-map AI drug discovery modules

Oct. 11, 2023

By Marian (YoonJee) Chu

Sanofi SA will pay $10 million up front and potentially $1 billion down the road to build artificial intelligence (AI) drug discovery modules with Biomap – the Silicon Valley-based biotech led by Chinese billionaire, software engineer and serial entrepreneur Robin Li known for founding China’s largest internet search engine and AI platform, Baidu, in 2000.

Post-Lumakras adcom, BMS makes $5.8B move for Mirati; Sanofi to counter?

Oct. 9, 2023

By Randy Osborne

Just as Wall Street had begun mulling the possible fallout of the regulatory vote against full U.S. FDA clearance for Amgen Inc.’s KRAS G12C therapy for non-small-cell lung cancer, a new – albeit not entirely unexpected – development cropped up in the space. Mirati Therapeutics Inc. disclosed Oct. 9 that Bristol Myers Squibb Co. (BMS) is offering to take over the firm in a deal that could be worth as much as $5.8 billion, historically one of the larger takeovers for 2023.